Dara Lily, Johnson Heather, Suda Jo, Win Sanda, Gaarde William, Han Derick, Kaplowitz Neil
University of Southern California Research Center for Liver Diseases, and the Division of GI-Liver, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
ISIS Pharmaceuticals, Carlsbad, CA.
Hepatology. 2015 Dec;62(6):1847-57. doi: 10.1002/hep.27939. Epub 2015 Jul 31.
Although necrosis in the acetaminophen (APAP) model is known to be regulated by c-Jun NH2-terminal kinase (JNK) through interaction with mitochondria, the role of necroptosis through receptor-interacting proteins 1 and 3 (RIPK1 and RIPK3) has also been suggested. Our aim was to determine the relationship between these two mechanisms of cell death. To verify the participation of RIPK1, we used antisense knockdown and confirmed protection comparable to the RIPK1 inhibitor, necrostatin, in vivo and in vitro. However, we found no evidence that RIPK3 is expressed in primary mouse hepatocytes under basal conditions or after APAP and RIPK3(-/-) mice were not protected. RIPK3 was exclusively expressed in nonparenchymal cells. RIPK1 knockdown protected RIPK3(-/-) mice to the same extent as wild-type mice, underscoring the independent role of RIPK1. We confirmed that necroptosis is not involved in APAP toxicity by using mixed lineage kinase domain-like protein (MLKL) knockout mice, which were not protected from APAP. Next, we addressed whether there is interplay between RIPK1 and JNK. RIPK1 knockdown decreased the level of JNK activation and translocation to mitochondria and abrogated subsequent translocation of dynamin-related protein 1 (Drp1). Interestingly, APAP induced translocation of RIPK1 to mitochondria, which was unaffected by knockdown of the mitochondrial JNK docking protein, Sh3 homology 3 binding protein 5 (Sab).
RIPK1 participates in APAP-induced necrosis upstream of JNK activation whereas RIPK3 and MLKL are dispensable, indicating that necroptosis does not contribute to APAP-induced necrosis and RIPK1 has a unique, independent role.
尽管已知对乙酰氨基酚(APAP)模型中的坏死是由c-Jun氨基末端激酶(JNK)通过与线粒体相互作用来调节的,但也有人提出受体相互作用蛋白1和3(RIPK1和RIPK3)介导的坏死性凋亡的作用。我们的目的是确定这两种细胞死亡机制之间的关系。为了验证RIPK1的参与,我们使用反义敲低技术,并在体内和体外证实了与RIPK1抑制剂坏死抑素相当的保护作用。然而,我们没有发现证据表明RIPK3在基础条件下或APAP处理后的原代小鼠肝细胞中表达,并且RIPK3基因敲除(-/-)小鼠没有受到保护。RIPK3仅在非实质细胞中表达。RIPK1敲低对RIPK3(-/-)小鼠的保护程度与野生型小鼠相同,这突出了RIPK1的独立作用。我们通过使用混合谱系激酶结构域样蛋白(MLKL)基因敲除小鼠证实坏死性凋亡不参与APAP毒性,这些小鼠没有受到APAP的保护。接下来,我们探讨RIPK1和JNK之间是否存在相互作用。RIPK1敲低降低了JNK的激活水平及其向线粒体的转位,并消除了随后动力相关蛋白1(Drp1)的转位。有趣的是,APAP诱导RIPK1向线粒体转位,这不受线粒体JNK对接蛋白Sh3同源性3结合蛋白5(Sab)敲低的影响。
RIPK 在 JNK 激活上游参与 APAP 诱导的坏死,而 RIPK3 和 MLKL 是不必要的,这表明坏死性凋亡不参与 APAP 诱导的坏死,并且 RIPK1 具有独特的独立作用。